1
|
Klersy A, Meyer S, Leuschner F, Kessler T, Hecker M, Wagner AH. Ectodomain Shedding by ADAM17 Increases the Release of Soluble CD40 from Human Endothelial Cells under Pro-Inflammatory Conditions. Cells 2023; 12:1926. [PMID: 37566005 PMCID: PMC10417149 DOI: 10.3390/cells12151926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 07/11/2023] [Accepted: 07/24/2023] [Indexed: 08/12/2023] Open
Abstract
BACKGROUND Homozygosity for the C allele of the -1T>C single nucleotide polymorphism (SNP) of the CD40 gene (rs1883832) is associated with susceptibility to coronary heart disease (CHD), enhanced CD40 expression, and shedding. The disintegrin metalloprotease ADAM17 can cleave various cell surface proteins. This study investigates an association between ADAM17-mediated CD40 shedding and inflammation in CC genotype human endothelial cells. METHODS Human umbilical vein endothelial cells (HUVEC) carrying the CC genotype were stimulated with soluble CD40 ligand (sCD40L) or tumor necrosis factor-α (TNFα). Messenger RNA and protein expression were determined with standard methods. Levels of high sensitive c-reactive protein (hs-CRP), interleukin-6 (IL-6), and sCD40 in plasma samples from patients with CHD were assessed using ELISA. RESULTS ADAM17 surface abundance was elevated following stimulation with CD40L and TNFα just as its regulator iRhom2. Inhibition of ADAM17 prevented TNFα-induced sCD40 and soluble vascular cell adhesion molecule-1 release into the conditioned medium and reinforced CD40 surface abundance. Secondary to inhibition of ADAM17, stimulation with CD40L or TNFα upregulated monocyte chemoattractant protein-1 mRNA and protein. Levels of sCD40 and the inflammatory biomarkers hs-CRP and IL-6 were positively correlated in the plasma of patients with CHD. CONCLUSIONS We provide a mechanism by which membrane-bound CD40 is shed from the endothelial cell surface by ADAM17, boosting sCD40 formation and limiting downstream CD40 signaling. Soluble CD40 may represent a robust biomarker for CHD, especially in conjunction with homozygosity for the C allele of the -1T>C SNP of the CD40 gene.
Collapse
Affiliation(s)
- Anton Klersy
- Department of Cardiovascular Physiology, Heidelberg University, 69120 Heidelberg, Germany
| | - Sören Meyer
- Department of Cardiology, Angiology and Pneumology, Heidelberg University, 69120 Heidelberg, Germany
| | - Florian Leuschner
- Department of Cardiology, Angiology and Pneumology, Heidelberg University, 69120 Heidelberg, Germany
| | - Thorsten Kessler
- Department of Cardiology, German Heart Centre Munich, Technical University of Munich, 80636 Munich, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, 80636 Munich, Germany
| | - Markus Hecker
- Department of Cardiovascular Physiology, Heidelberg University, 69120 Heidelberg, Germany
| | - Andreas H. Wagner
- Department of Cardiovascular Physiology, Heidelberg University, 69120 Heidelberg, Germany
| |
Collapse
|
2
|
Wu HH, Ralph KL, Sepuldeva E, Hansen G, Li H, Huang ZF, Liu D, Dziegelewski M, Ahlberg J, Frego L, Fogal S, van Tongeren S, Grimaldi C, Litzenberger T, Presky D, Singh S, Brodeur S, Kroe-Barrett R. An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. Int J Pharm 2021; 609:121162. [PMID: 34624444 DOI: 10.1016/j.ijpharm.2021.121162] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Revised: 09/30/2021] [Accepted: 10/03/2021] [Indexed: 12/13/2022]
Abstract
Antibodies targeting the CD40-CD40L pathway have great potential for treating autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus (SLE), lupus nephritis (LN), and inflammatory bowel diseases (IBD). However, in addition to the known difficulty in generating a purely antagonistic CD40 antibody, the presence of CD40 and CD40L on platelets creates additional unique challenges for the safety, target coverage, and clearance of antibodies targeting this pathway. Previously described therapeutic antibodies targeting this pathway have various shortcomings, and the full therapeutic potential of this axis has yet to be realized. Herein, we describe the generation and characterization of BI 655064, a novel, purely antagonistic anti-CD40 antibody that potently neutralizes CD40-CD40L-dependent B-cell stimulation without evidence of impacting platelet functions. This uniquely optimized antibody targeting a highly challenging pathway was obtained by applying stringent functional and biophysical criteria during the lead selection process. BI 655064 has favorable target-mediated drug disposition (TMDD)-saturation pharmacokinetics, consistent with that of a high-quality therapeutic monoclonal antibody.
Collapse
Affiliation(s)
- Helen Haixia Wu
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.
| | - Kerry-Leigh Ralph
- Boehringer Ingelheim Pharmaceuticals, Inc. Cancer Immunology & Immune Modulation, Ridgefield, CT, USA
| | - Eliud Sepuldeva
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Gale Hansen
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Hua Li
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Zhong-Fu Huang
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Dongmei Liu
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Michael Dziegelewski
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Jennifer Ahlberg
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Lee Frego
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| | - Steve Fogal
- Boehringer Ingelheim Pharmaceuticals, Inc. Immunology & Respiratory, Ridgefield, CT, USA
| | - Susan van Tongeren
- Boehringer Ingelheim Pharmaceuticals, Inc. Nonclinical Drug Safety, Ridgefield, CT, USA
| | - Christine Grimaldi
- Boehringer Ingelheim Pharmaceuticals, Inc. Drug Metabolism and Pharmacokinetics, Ridgefield, CT, USA
| | - Tobias Litzenberger
- Boehringer Ingelheim Pharmaceuticals, Inc. Translational Medicine & Clinical Pharmacology, Biberach, B-W, Germany
| | | | - Sanjaya Singh
- Janssen Biotherapeutics at Johnson & Johnson. Spring House, PA, USA
| | - Scott Brodeur
- Janssen Pharmaceutical Companies at Johnson & Johnson. New Jersey, PA, USA
| | - Rachel Kroe-Barrett
- Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA
| |
Collapse
|
3
|
Bachsais M, Salti S, Zaoui K, Hassan GS, Aoudjit F, Mourad W. CD154 inhibits death of T cells via a Cis interaction with the α5β1 integrin. PLoS One 2020; 15:e0235753. [PMID: 32745080 PMCID: PMC7398495 DOI: 10.1371/journal.pone.0235753] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 06/22/2020] [Indexed: 12/30/2022] Open
Abstract
CD154 plays a major role in the pathogenesis of several autoimmune and inflammatory diseases. In addition to CD40, soluble CD154 (sCD154) binds to other receptors namely αIIbβ3, αMβ2, α5β1 and αvβ3 integrins. We have previously reported that binding of sCD154 to α5β1 integrin expressed on several human T cell lines is capable of inhibiting Fas-induced cell death. In the current study, we show that such effect of the sCD154/α5β1 interaction is not restricted to the cell death response induced by Fas but could also be exhibited toward other death signals such as TRAIL and TNF- α. We also demonstrate that sCD154 is capable of inhibiting Fas-mediated death of human activated T cells, more importantly of CD4+ than CD8+ T ones. Our data also show that membrane-bound CD154 and α5β1 integrin expressed on the surface of distinct cells failed to influence cell death responses. However, when membrane-bound CD154 and α5β1 are expressed on the surface of same cell, their interaction was capable of down regulating cell death. CD154 was shown to co-localize with the α5β1 integrin on the surface of these cells. These data strongly suggest a cis-type of interaction between CD154 and α5β1 when both are expressed on the same cell surface, rather than a trans-interaction which usually implicates the ligand and its receptor each expressed on the surface of a distinct cell. Taken together, these findings add to the list of roles through which CD154 is contributing to the pathogenesis of autoimmune-inflammatory diseases, i.e. by protecting T cells from death and enhancing their survival.
Collapse
Affiliation(s)
- Meriem Bachsais
- Laboratoire d’Immunologie Cellulaire et Moléculaire, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Montréal, Québec, Canada
| | - Suzanne Salti
- Laboratoire d’Immunologie Cellulaire et Moléculaire, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Montréal, Québec, Canada
| | - Kossay Zaoui
- Laboratoire d’Immunologie Cellulaire et Moléculaire, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Montréal, Québec, Canada
| | - Ghada S. Hassan
- Laboratoire d’Immunologie Cellulaire et Moléculaire, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Montréal, Québec, Canada
| | - Fawzi Aoudjit
- Centre de recherche du CHU de Québec-Université Laval, Québec, Québec, Canada
| | - Walid Mourad
- Laboratoire d’Immunologie Cellulaire et Moléculaire, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM), Montréal, Québec, Canada
- * E-mail:
| |
Collapse
|
4
|
Therapeutic effects of anti-CD154 antibody in cynomolgus monkeys with advanced rheumatoid arthritis. Sci Rep 2018; 8:2135. [PMID: 29391506 PMCID: PMC5794761 DOI: 10.1038/s41598-018-20566-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 01/19/2018] [Indexed: 01/29/2023] Open
Abstract
Rheumatoid arthritis is one major chronic inflammatory systemic autoimmune disease. The CD154-CD40 interactions play a critical role in the regulation of immune responses and the maintenance of autoimmunity. Therefore, we aimed to determine whether anti-CD154 antibody treatment show positive effects on immunomodulation and clinical improvement of sustained severe rheumatoid arthritis in cynomolgus monkeys. Arthritis was induced using chicken type II collagen (CII) and arthritic monkey were divided into control and anti-CD154 treatment groups based on their concentrations of anti-CII antibodies on week 7 post-immunization. Blood and tissue samples were collected on week 16 post-immunization. Anti-CD154 antibody treatment improved arthritis and movement, and significantly decreased the numbers of proliferating B cells and the serum levels of anti-type II collagen antibody and sCD154 compared with non-treatment group. Further anti-CD154 antibody treatment significantly decreased the percentage of CD4+ cells and the ratio of CD4+ to CD8+ T cells and significantly increased the percentage of CD8+ cells and effector memory CD8+ cells in peripheral blood. We have shown for the first time in a nonhuman primate model of RA that CD154 blockade has beneficial effects. This study might be valuable as preclinical data of CD154 blockade in nonhuman primate models of severe rheumatoid arthritis.
Collapse
|
5
|
Pan Y, Zhou F, Song Z, Huang H, Chen Y, Shen Y, Jia Y, Chen J. Oleanolic acid protects against pathogenesis of atherosclerosis, possibly via FXR-mediated angiotensin (Ang)-(1-7) upregulation. Biomed Pharmacother 2018; 97:1694-1700. [PMID: 29793333 DOI: 10.1016/j.biopha.2017.11.151] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Revised: 11/30/2017] [Accepted: 11/30/2017] [Indexed: 02/08/2023] Open
Abstract
Atherosclerosis, the leading cause of cardiovascular diseases in the world, is a chronic inflammatory disorder characterized by the dysfunction of arteries. Oleanolic acid (OA) is a bioactive nature product which exists in various plants and herbs. Previous studies have demonstrated that OA was involved in numerous of biological processes, including atherosclerosis. However, the exact mechanisms of the anti-atherosclerosis effects of OA remain unknown. Here, in our study, we analyzed the effects and possible underlying mechanisms of OA in atherosclerosis depending a cell model and an animal model of atherosclerosis. Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL, 100 μg/mL) for 24 h to establish an atherosclerotic cell model. New Zealand white (NZW) rabbits were fed with high-fat (HF) diets for three months to establish an atherosclerotic animal model. Then, cell viability and expression of cytokines (ANG, NO, eNOS, IL-1β, TNF-α, and IL-6) were measured with CCK-8 assay and ELISA kits, cell apoptosis and cell cycle distribution were analyzed by flow cytometry in the atherosclerotic cell model. Results showed that ox-LDL induced effects of anti-proliferation, cytokines alterations, and cell apoptosis were abolished by the application of OA or Ang (1-7). Further study indicated that OA increased the expression of ANG by upregulating the FXR expression in the ox-LDL induced HUVECs arthrosclerosis model. And the in vivo experiment in the HF diet induced animal model suggested that OA may inhibit the development of atherosclerosis. The atherosclerosis of aortas was assessed by Hematoxylin Eosin (HE), Oil Red O and Picrosirius Red staining; the expression levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C) were determined by the fully automatic biochemical analyzer, in the atherosclerotic animal model. All the results showed that OA treatment improved the cell viability in the cell model, inhibited the atherosclerosis development in the animal model. OA play as an anti-atherosclerosis agent in both the cell model and animal model by upregulating the production of Angiotensin (Ang)-(1-7) through FXR.
Collapse
Affiliation(s)
- Yunyun Pan
- Department of Pharmaceutical, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China; Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510080, China
| | - Fenghua Zhou
- School of Traditional Chinese Medicine, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, China
| | - Zhenhua Song
- The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China
| | - Huiping Huang
- Department of Pharmaceutical, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China; Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510080, China
| | - Yong Chen
- Department of Pharmaceutical, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China; Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510080, China
| | - Yonggang Shen
- Department of Pharmaceutical, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China; Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510080, China
| | - Yuhua Jia
- School of Traditional Chinese Medicine, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, China.
| | - Jisheng Chen
- Department of Pharmaceutical, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, China; Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510080, China.
| |
Collapse
|
6
|
Simic D, Bogdan N, Teng F, Otieno M. Blocking α5β1 Integrin Attenuates sCD40L-Mediated Platelet Activation. Clin Appl Thromb Hemost 2015; 23:607-614. [PMID: 26719354 DOI: 10.1177/1076029615624549] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The soluble form of CD40L (sCD40L) is a platelet-derived mediator that links inflammation, hemostasis, and vascular dysfunction. Indeed, blockade of CD40L by neutralizing antibodies or genetic disruption in mice prevents atherosclerosis and atherothrombosis. Until recently, it was believed that CD40 and αIIbβ3 were the only receptors on platelets responsible for binding sCD40L, leading to platelet activation and initiation of thrombotic events. Recent findings showed α5β1 integrin as a novel platelet sCD40L receptor, with an unknown function. For the first time, using anti-α5β1 blocking antibodies, we show that sCD40L/α5β1 interaction leads to platelet activation as evaluated in the human whole blood. Establishing α5β1 integrin's role in platelet activation, and therefore thrombosis will help further shed light on the etiology of thrombotic disease.
Collapse
Affiliation(s)
- Damir Simic
- 1 Preclinical Development & Safety, Janssen Research & Development, LLC, Spring House, PA, USA
| | - Nancy Bogdan
- 1 Preclinical Development & Safety, Janssen Research & Development, LLC, Spring House, PA, USA
| | - Fang Teng
- 2 Biologics Discovery Sciences, Spring House, Janssen Research & Development, LLC, PA, USA
| | - Monicah Otieno
- 1 Preclinical Development & Safety, Janssen Research & Development, LLC, Spring House, PA, USA
| |
Collapse
|
7
|
Reichwald K, Jørgensen TZ, Skov S. TL1A increases expression of CD25, LFA-1, CD134 and CD154, and induces IL-22 and GM-CSF production from effector CD4 T-cells. PLoS One 2014; 9:e105627. [PMID: 25148371 PMCID: PMC4141816 DOI: 10.1371/journal.pone.0105627] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Accepted: 07/22/2014] [Indexed: 12/03/2022] Open
Abstract
Elevated levels of the cytokine TL1A is associated with several autoimmune diseases e.g. rheumatoid arthritis and inflammatory bowel disease. However, the exact role of TL1A remains elusive. In this study, we investigated the function of TL1A in a pro-inflammatory setting. We show that TL1A together with IL-12, IL-15 and IL-18 increases expression of the co-stimulatory molecules CD154 (CD40 ligand) and CD134 (OX40) on previously activated CD4+ T cells. This indicates that TL1A functions as a co-stimulatory molecule, decreasing the activation threshold of T-cells. We have previously shown that TL1A co-stimulation strongly induces IL-6 in human healthy leukocytes. Interestingly, the cytokine-activated effector T-cells did not produce IL-6 in response to TL1A, indicating distinct effects of TL1A on different cell populations. We further show that this co-stimulation increases the expression of CD25 (IL-2Rα) and CD11a (α-chain of LFA-1) on CD4 T-cells, likely governing increased IL-2/IL-15 sensitivity and cell-cell contact. Along with this, TL1A co-stimulation caused a specific induction of IL-22 and GM-CSF from the activated T-cells. These results substantially contribute to the explanation of TL1A's role in inflammation. Our results suggest that TL1A should be considered as a target for immunotherapeutic treatment of rheumatoid arthritis and inflammatory bowel disease.
Collapse
Affiliation(s)
- Kirsten Reichwald
- Section for Experimental Animal Models, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Tina Z. Jørgensen
- Section for Experimental Animal Models, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Søren Skov
- Section for Experimental Animal Models, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|